Amgen looks to jump-start academic research; Bayer eyes animal health deals;

@FierceBiotech: Buzz: Cellectis could be in a line for a $1.6B Pfizer buyout. Article | Follow @FierceBiotech

@JohnCFierce: Is this a good time to tout my survey (with Bloomberg Intelligence)? Are biotech assets overvalued? Check it out | Follow @JohnCFierce

> Amgen ($AMGN) is offering up a catalog of research tools and reagents to academic institutions with the goal of jump-starting projects in biology, launching the Amgen Biology-Enabling Resource, or AmBER. News

> Bayer's impending move to spin off its plastics business is soon to give the drugmaker a large cash sum, and CEO Marijn Dekkers said the company may splurge to bolster its animal health division. Item

Medical Device News

@FierceMedDev: ICYMI yesterday: Deerfield backs startup with $10M for its hemodialysis vascular access implant. Article | Follow @FierceMedDev

@VarunSaxena2: UPDATED w/ info from the company: CareFusion's Avea ventilator recalled as potentially deadly. Story | Follow @VarunSaxena2

@EmilyWFierce: Boston Scientific slapped with $100M verdict in vaginal mesh suit. News | Follow @EmilyWFierce

> Zimmer ($ZMH) to divest three U.S. businesses to appease FTC, hit mid-June Biomet acquisition close. More

> Nonprofit leads $17.5M round for medical image exchange startup LifeImage. Article

Pharma News

@FiercePharma: Tech makers market health wearables to dog owners. FierceAnimalHealth story | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Lundbeck's EU lobbying yields political boost for anti-alcohol med Selincro. Article | Follow @CarlyHFierce

> Bayer chief may plow spinoff cash into animal health buys. Article

> Betting on Pfizer ($PFE) merger--or CEO goodbye--traders go bullish on Glaxo ($GSK). Story

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.